INTRODUCTION
Tumor necrosis factor (TNF) inhibitoreinduced palmoplantar pustulosis (PPP) can present with debilitating, refractory disease that requires changing or stopping anti-TNF agents or adding systemic treatments. Here, we report an update of a previously reported case of severely recalcitrant PPP successfully treated with the Janus kinase (JAK) inhibitor tofacitinib.
CASE REPORT
A white woman in her 40s initially presented with vesiculopustules on her palms and soles, clinically diagnosed as PPP, in the setting of adalimumab treatment for Crohn's disease. Despite cessation of adalimumab, the patient's eruption persisted. Throughout the course of her care, she failed to respond to multiple treatment regimens (Table I) . Eventually, she had complete clearance after 4 doses of ustekinumab 45 mg subcutaneous injections, with remission achieved for several months, and her case was reported in Archives of Dermatology. Over time, however, the patient experienced worsening of her disease and subsequently failed to improve despite an increased dose of 90 mg ustekinumab. Because of debilitating symptoms, she was intermittently treated with cyclosporine at low doses. She had complete clearance temporarily while taking a combination of apremilast and tocilizumab, but she was unable to be tapered off either medication without a recurrence of symptoms, and she ultimately relapsed with active disease despite combination therapy. She was started on tofacitinib 5 mg tablets twice daily. Since initiation of this medication, her PPP has cleared completely without intermittent flares (Fig 1, A-D) . During a follow-up period of 1 year after initiation of tofacitinib, she was able to discontinue all other topical and systemic immunosuppressive agents. Her Crohn's disease was in remission for the duration of her treatment for PPP, without flares of her gastrointestinal disease on any of the medications.
DISCUSSION
Because TNF inhibitoreinduced PPP remains a relatively uncommon, understudied phenomenon, its pathophysiology and long-term treatment have Tofacitinib is an oral JAK inhibitor that inhibits the JAKesignal transducer and activator of transcription pathway, with the greatest effect on JAK1 and JAK3. It decreases the production of a multitude of cytokines, most notably interferon g, interleukin 6, and interleukin 17A, 2 which have been shown to play a role in the pathogenesis of PPP. 3 However, because tofacitinib has also been implicated as a trigger for PPP, additional cytokines may be involved. 4 Consistent with our current findings, a previous case report has shown the success of tofacitinib for recalcitrant TNF inhibitoreinduced PPP in the setting of rheumatoid arthritis treatment. 5 We recommend consideration of the use of tofacitinib as a potential long-term management agent for refractory TNF inhibitoreinduced PPP. We also hope to encourage further investigation of this agent. 
